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THE DESPERATE NEED TO INCLUDE PREGNANT WOMEN IN CLINICAL 
RESEARCH: PROPOSED RECOMMENDATIONS TO INCREASE ENROLLMENT OF 
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 1 
INTRODUCTION 
 
The lack of human data available to make evidence-based decisions about 
medicine taken during pregnancy has heightened awareness that pregnant women should 
be included in biomedical research.1 However, regulations, guidance, and the current 
clinical trial landscape reflect an exclusionary approach to research. This paper explores 
the lack of data available for pregnant women and healthcare practitioners to make 
informed decisions about the safety of medication taken during pregnancy and changes 
the federal government could make in an attempt to increase knowledge and data for 
medications taken during a pregnancy. 
The CDC estimates that 133 million Americans, almost one out of every two 
adults, have at least one chronic illness.2 Many pregnant women have medical conditions 
that require prescription medications, yet most drugs are approved without any clinical 
research on their safe use during pregnancy. 3  These untested medications may treat 
preexisting chronic conditions such as diabetes or seizures. 4  A study describing 
medication use during pregnancy showed that the overall use has increased during the 
past 30 years, and a majority of women took at least one prescription drug during 
pregnancy.5 The failure to understand the risks and benefits of medication use during 
pregnancy can result in inadvertent exposure to the fetus, pregnancy termination, or 
                                                        
1 See infra notes 5–12, and accompanying text. 
2 Chronic Diseases and Health Promotion, CDC.GOV, 
http://www.cdc.gov/chronicdisease/overview/index.htm (last visited Mar. 11, 2014). 
3 Pregnancy Research, CDC.GOV, http://www.cdc.gov/pregnancy/meds/research.html (last visited Mar. 11, 
2014). 
4 Pellavi Sharma, et al., An Innovative Approach To Determine Fetal Risk, 18 WOMEN’S HEALTH ISSUES, 
226, 228 (2008).  
5 Allen Mitchell et al., Medication use during pregnancy, with particular focus on prescription drugs: 
1976-2008, 205 AM. J. OBSTETRICS & GYNECOLOGY 51.e1 (2011). 
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alternatively, discontinuation in medication that may cause maternal or fetal harm.6 
However, there is reluctance to conduct clinical research in pregnant women 
because of ethical concerns. Pregnant women are a challenging population to conduct 
research because of concerns of potential adverse effects of medication exposure to the 
developing fetus.7 For example, it would be unethical to randomize pregnant women to 
receive antidepressant drugs with unknown safety profiles. 8  Although there may be 
situations when exclusion of pregnant women from research is justified, because of 
ethical concerns, pregnant women are often reflexively excluded.9 
A major concern for taking medication during pregnancy is the potential for fetal 
adverse effects, or that drug pharmacokinetics are “commonly altered in pregnancy, 
potentially affecting optimal dosing.”10 Except for the few products developed to treat 
conditions unique to pregnancy, prescription drugs are not tested in pregnant women 
prior to their approval, resulting in no data from controlled clinical trials.11 Risks and 
benefits for the mother and fetus must carefully be weighed before prescribing, yet is a 
challenge because of the scarcity of information available.12 
Part I of this paper examines the historical background of women’s participation 
                                                        
6 Lydia E. Pace & Eleanor Bimla Schwarz, Balancing act: safe and evidence-based prescribing for women 
of reproductive age, 8 J. WOMEN’S HEALTH 415, 416 (2012). 
7 Meghan Coakley, et al., Dialogues on Diversifying Clinical Trials: Successful Strategies for Engaging 
Women and Minorities in Clinical Trials, 21 J. WOMEN'S HEALTH 713 (2012). 
8 Fabiano Santos et. al. Quality Assessment of Clinical Practice Guidelines for the Prescription of 
Antidepressant Drugs During Pregnancy, 7 CURRENT CLINICAL PHARMACOLOGY 7, 8 (2012). 
9 Kristine Shields & Anne Drapkin Lyerly, Exclusion of Pregnant Women From Industry-Sponsored 
Clinical Trials, 122 AM. C. OBSTETRICIANS & GYNECOLOGISTS 1077 (2013). 
10 Simon Thomas & Laura Yates, Prescribing without evidence – pregnancy, 74 BRIT. J. CLINICAL 
PHARMACOLOGY 691, 692 (2012).  
11 Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for 
Pregnancy and Lactation Labeling, 73 Fed. Reg. 30831-01, 30841 (proposed May 29, 2008) (to be codified 
at 21 C.F.R. pt. 201). 
12 Thomas & Yates, supra note 10 at 691; See also Paul Doering, et al., Review of pregnancy labeling of 
prescription drugs: Is the current system adequate to inform of risks? AM. J. OBSTETRICS & GYNECOLOGY 
333, 335 (2002). 
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in clinical trials. Part II reviews the lack of evidence-based data for medication taken 
during pregnancy. Part III assesses current regulations and guidance, and explains why 
they are unsatisfactory. Part IV evaluates the current landscape of clinical research in 
pregnant women in order to demonstrate the consequences of the lack of scientific data. 
Part V recommends changes to federal regulations, or in the alternative, an incentive-
based program to increase the enrollment of pregnant women in clinical research. 
I. HISTORICAL EVOLUTION OF WOMEN AND CLINICAL RESEARCH – FROM COMPLETE 
EXCLUSION TO AN EXCLUSIONARY APPROACH 
A. History of Women As Research Subjects Before Guidelines & Congressional 
Response to Exclude Women as Research Subjects 
 
 During the early nineteenth century, clinical trials depended upon the 
experimentation of surgical procedures and methods on female American slaves, 
followed by institutionalized populations and prisoners in the twentieth century. 13 
Following the exposure of German brutalities during World War II, the Nuremberg Code 
created the first internationally recognized standards for human research.14  
In 1953, the Clinical Center at the National Institutes of Health established a 
policy for the protection of human subjects. 15  For NIH clinical research, this policy 
required informed consent of all subjects, and review and approval of research. 16 
 Following the NIH policies, Congress began to issue a number of laws and 
standards for the protection of human subjects in research. In 1962, Congress passed the 
Drug Amendments, which required that researchers testing investigational new drugs 
                                                        
13 See Ruth B. Merkatz & Suzanne W. Junod, Historical Background of Changes in FDA Policy on the 
Study and Evaluation of Drugs in Women, 69 ACAD. MED. 703 (1994). 
14 Id. 
15 Joseph L. Breault, Protecting Human Research Subjects: The Past Defines the Future, 6 OCHSNER J. 15, 
20 (2006). 
16 Id. 
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now had to obtain consent from research subjects.17  
In 1974, Congress passed the National Research Act that mandated approval by 
an IRB of human subjects research at any institution receiving DHHS funding.18 This 
extended additional protections to research subjects of biomedical research, development, 
and related activities involving, among other groups, fetuses, and pregnant women.19  
However, in 1977 the FDA issued a guideline for drug development 
recommending that women of childbearing potential be excluded from clinical drug 
trials.20 This exclusion was applied broadly to any “premenopausal female being capable 
of becoming pregnant.”21  Although this exclusion was applicable to only women of 
childbearing potential from early phases of drug trials, investigators and IRBs applied 
this to all phases of drug trials.22  
B. Shift Away from Excluding Women in Clinical Research 
In 1986 NIH policy was changed to encourage the inclusion of women in research 
to require a justification for exclusion of women as well as evaluate gender differences in 
the future.23, 24 In 1990, the Women’s Health Equity Act was passed, and the Office for 
                                                        
17 Id. 
18 Id. 
19 Protection of Human Subjects, 45 C.F.R. § 46 (1975).  
20 U.S. DEPT. OF HEALTH & HUMAN SERVS., FOOD & DRUG ADMIN., GENERAL CONSIDERATIONS FOR THE 
CLINICAL EVALUATION OF DRUGS 7 (1977).  
21 Id. See also Marianne Prout & Susan Fish, Participation of women in clinical drug trials of drug 
therapies: a context for the controversies, 3 MEDSCAPE GEN. MED. 4 (2001) (noting that the exclusion from 
drug trials also included all women using contraception, women with male partners, and single women; and 
concluding that changes were prompted from public and political attention by the thalidomide tragedy 
which resulted in over 10,000 children with birth defects worldwide to focus on drug approval processes). 
22 Janet E. Shepard, Women and Health Research: Ethical and Legal Issues of Including Women in Clinical 
Studies 272 JAMA 1467 (1994). 
23 U.S. DEP’T OF HEALTH & HUMAN SERVICES, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF 
HEALTH, OFFICE OF RESEARCH ON WOMEN’S HEALTH, ENROLLING PREGNANT WOMEN: ISSUES IN CLINICAL 
RESEARCH (2011), available at http://orwh.od.nih.gov/resources/policyreports/pdf/ORWH-EPW-Report-
2010.pdf (noting that the historical research tragedies were due to the problem that research had not been 
conducted to validate the use of the product).  
24 See Maternal-Fetal Medicine Units (MFMU) Network, NICHD.NIH.GOV, 
http://www.nichd.nih.gov/research/supported/Pages/mfmu.aspx (last visited May 6, 2014) (also in 1986, 
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Research on Women’s Health was established.25 The NIH Revitalization Act of 1993 
required that women must be included in all NIH-funded clinical research, unless a clear 
and compelling rationale and justification established that inclusion is inappropriate with 
respect to the health of the subjects or the purpose of the research.26 Specifically, this 
policy states that women of childbearing potential should not be routinely excluded from 
participation in clinical research.27 The Act does not address research in pregnant women. 
In 1993, the FDA lifted the 1977 guideline excluding women of childbearing 
potential.28 This notice explained that subgroup-specific differences in response can arise 
because of variations in a drug’s pharmacokinetics or pharmacodynamics.29 The FDA 
acknowledged that the removal of the prohibition on participation of women of 
childbearing potential was consistent with congressional efforts to prevent unwarranted 
discrimination against women. 30  While these guidelines removed the prohibition of 
women in clinical trials, the FDA did not require female participation, nor did it address 
potential benefits of including pregnant women. A lack of direction in combination with 
advice to avoid pregnancy highlights the ethical dilemma of enrollment.31 The Food and 
Drug Administration Modernization Act of 1997 mandated the review and development 
                                                                                                                                                                     
the NIH Child Health and Human Development established the Maternal-Fetal Medicine Units Network to 
response to the need for well-designed clinical trials within maternal-fetal medicine, specifically preterm 
birth, with a focus to evaluate interventions for efficacy, safety and cost-effectiveness). 
25 Id. 
26 See NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical 
Research, NIH.GOV, http://grants1.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm 
(last visited Mar. 11, 2014). 
27 Id. 
28 Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs, 58 
Fed. Reg. 39,406, 39,409–11 (July 22, 1993) [hereinafter the 1993 FDA GUIDELINE]. 
29 Id. 
30 Id. 
31 See 1993 FDA GUIDELINE, 58 Fed. Reg. 39,406 (the notice stated that precautions against becoming 
pregnant and exposing a fetus should be taken by women participating in clinical trials). 
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of guidance on the inclusion of women in clinical trials.32  
In 1998, Congress passed a final rule that required New Drug Applications 
(NDAs) to present effectiveness and safety data for important demographic subgroups, 
specifically gender.33 This rule also required sponsors to tabulate in their annual reports 
the numbers of subjects enrolled to date in clinical studies for drug and biological 
products according to age group, gender, and race in Investigational New Drugs 
(INDs).34 
In 2014, the CDC launched an initiative, Treating for Two: Safer Medication Use 
in Pregnancy, to improve the quality of data and information on medication use during 
pregnancy. 35  The initiative seeks to expand medication safety research, evaluate 
evidence, and educate women and healthcare providers.36 
II. LACK OF EVIDENCE-BASED DATA FOR MEDICATION TAKEN DURING PREGNANCY IS A 
GRAVE ISSUE 
 
 Pregnant women need safe and effective treatment options, but are left with a 
severe lack of scientific data to support which option may be best during their pregnancy 
due to legal and ethical concerns. Pregnant women are severely underrepresented in the 
clinical research process, with the environment today as contrary to the core of social 
                                                        
32See Participation of Females in Clinical Trials and Gender Analysis of Data in Biologic Product 
Applications, FDA.GOV, 
http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/InvestigationalNewDrugINDo
rDeviceExemptionIDEProcess/ucm094300.htm (last visited May 6, 2014) (explaining that the OWH 
research project examined the extent to which females have been included in clinical trials for biological 
products and to what extent the data from these studies have been analyzed and presented with respect to 
gender. The FDA formed the “FDAMA women and minorities working group” with representatives from 
the agency and the NIH to implement the section of the Act mandating the review and development of 
guidance, as appropriate, on the inclusion of women in clinical trials). 
33 Investigational New Drug Applications and New Drug Applications, 63 Fed. Reg. 6854-02 (Feb. 11, 
1998) (to be codified at 21 C.F.R. pt. 312, 314). 
34 Id. 
35 Medications and Pregnancy, CDC.GOV, http://www.cdc.gov/pregnancy/meds/ (last visited Apr. 18, 
2014). 
36 Treating for Two, CDC.GOV, http://www.cdc.gov/pregnancy/meds/treatingfortwo/facts.html (last visited 
Apr. 18, 2014). 
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justice, where you treat others as dignified beings deserving of equal moral concern and 
to view others as independent sources of moral worth and dignity.37  This is not the 
standard adhered to because pregnant women are not afforded the same attention and 
rigorous research as other populations.38 
 The FDA Office of Women’s Health (OWH) advocates for the participation of 
women in clinical trials to better understand the biologic basis for sex differences because 
research has shown that sex as a variable contributes to differences in the safety and 
efficacy of drugs, biologics, and devices.39  Data show that women experience more 
adverse drug reactions than men, and these reactions tend to be severe.40 The 2001 GAO 
report found that of ten prescription drugs taken off the market by the FDA due to 
adverse events, eight were associated with greater health risks in women than men.41 
In the past, most products approved by the FDA were studied exclusively in men 
in order to obtain FDA approval.42 Pharmacological response may differ between men 
and women, with an increase of identification of sex-gender pharmacodynamic 
differences at a molecular level, however, these differences are understudied in women.43 
For example, in 2013 the FDA cut the recommended dose of zolpidem in half for women, 
                                                        
37 Mary Foulkes, et al., Clinical Research Enrolling Pregnant Women: A Workshop Summary, 20 J. 
WOMEN’S HEALTH 1429, 1432 (2011). 
38 Id. 
39 Understanding Sex Differences, FDA.GOV, 
http://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm131182.htm (last visited 
Apr. 18, 2014). 
40 Donald Mattison & Anne Zajicek, Gaps in Knowledge in Treating Pregnant Women, 3 GENDER MED. 
169, 172 (2006).  
41 Id. 
42 Inside Clinical Trials: Testing Medical Products in People, FDA.GOV, 
http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143531.htm (last visited Apr. 18, 2014). 
43 Flavia Franconi & Ilaria Campesi, Pharmacogenomics, Pharmacokinetics & Pharmacodynamics: 
Interaction With Biological Differences Between Men And Women, 171 BRIT. J. PHARMACOLOGY 580 
(2014).  
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making this the only prescription in the U.S. with a different suggested dose by gender.44 
 Pregnancy further affects the ability of drug distribution, absorption, metabolism, 
and elimination.45 Changes in the body’s physiology during pregnancy may require the 
healthcare practitioner to increase or decrease a dose.46 Specifically, pregnancy places 
different demands on the mother’s circulatory system because the uterus and placenta 
require additional blood, increasing plasma volume faster than the blood cells increase.47 
This increase of blood volume requires extra work from the heart and kidneys, leaving a 
possibility that the drug may be excreted through a pregnant woman’s kidneys faster than 
normal. 48  These changes also depend on the stage of pregnancy, so there may be 
clinically important changes in drug concentrations between various trimesters of 
pregnancy.49 
 A healthcare practitioner must blindly alter dosage for a pregnant woman because 
research was not conducted in this population. A 2011 study of all medications approved 
by the FDA from 1980 to 2010 found that 91% of the medications approved for use by 
adults did not have sufficient data for the use and risks of medication taken during 
pregnancy.50 With the well known fact that the human body responds differently during 
pregnancy, it is unacceptable that this population is underrepresented in clinical research. 
The largest study conducted on drug use during pregnancy is a 2004 retrospective 
study that evaluated the experience of pregnant women, and concluded that 64% of 
                                                        
44 Lesley Stahl, Sex matters: Drugs can affect sexes differently, CBS NEWS (Feb. 9, 2014), available at 
http://www.cbsnews.com/news/sex-matters-drugs-can-affect-sexes-differently/. 
45 Mattison & Zajicek, supra note 40.  
46 Michelle Meadows, Pregnancy and the Drug Dilemma, 35 FDA CONSUMER 16, 18 (2001). 
47 Id. 
48 Id. 
49 Thomas & Yates, supra note 10 at 693. 
50 MP Adam et al., Evolving knowledge of the teratogenicity of medications in human pregnancy, 157 AM. 
J. MED. GENET. 175 (2011). 
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pregnant women took a prescription drug before delivery.51 Researchers also concluded 
“approximately one half of all pregnant women are prescribed drugs for which there is no 
evidence of safety during pregnancy in humans or for which there is evidence of fetal risk 
in animals or humans.”52 An additional complication is that studies performed in animals 
are of limited value because adverse events may be species specific. 53  This further 
demonstrates the need to change the way research is conducted in order to gather data for 
prescription medications that are taken during pregnancy. A 2010 study showed that over 
the last three decades, first trimester use of prescription medicine increased by more than 
60%, and the use of four or more medications more than tripled.54 This study suggests 
there is also an increase of practitioners prescribing medications in addition to taking 
medication during pregnancy without pharmacokinetic data.  
III. CURRENT REGULATIONS AND GUIDANCE 
 DHHS regulations governing the protection of human subjects in research contain 
five subparts.  Subpart A is the basic set of protections for all human subjects of research 
conducted or supported by HHS; this subpart is known as the Common Rule, because it 
has been adopted in identical form by 15 federal departments and agencies.  The DHHS 
regulations also contains subparts B, C and D, which provide added protections for 
specific vulnerable groups of subjects, including pregnant women, prisoners and children, 
and subpart E, which governs IRB registration.55  
 The FDA is a DHHS agency that regulates clinical investigations of drugs, 
                                                        
51 Susan E. Andrade et al., Prescription drug use in pregnancy, 191 AM. J. OBSTETRICS & GYNECOLOGY 
398 (2004). 
52 Id. 
53 Thomas & Yates, supra note 10 at 692. 
54 Mitchell et al., supra note 5. 
55 Regulations, HHS.GOV, http://www.hhs.gov/ohrp/humansubjects/index.html (last visited May 6, 2014). 
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biological products and medical devices and has adopted and codified subparts A and D 
as FDA human subject protection regulations.56 The FDA has not adopted regulations 
outlining special protections for pregnant women, fetuses or prisoners.57 
A. DHHS 45 C.F.R. Subpart B: Protection of Human Subjects 
 Under subpart B, pregnant women may participate in research:58 
a. Where scientifically appropriate, preclinical studies, including studies on 
pregnant animals and clinical studies, have been conducted and provide 
data for assessing potential risks to pregnant women; 
b. The risk to the fetus is caused solely by interventions or procedures that 
hold out the prospect of direct benefit for the woman or fetus; or, if there 
is no prospect of benefit, the risk to the fetus is not greater than minimal; 
c. Any risk is the least possible for achieving the objectives of the research; 
d. If the research holds out the prospect of direct benefit to the pregnant 
woman, the prospect of a direct benefit both to the pregnant woman and 
the fetus, or no prospect of benefit for the woman nor the fetus when the 
risk to the fetus is not greater than minimal, and her consent is properly 
obtained; 
e. If the research holds out the prospect of direct benefit solely to the fetus 
then the consent of the pregnant woman and the father is properly 
obtained, except if the father is unable to consent because of 
unavailability, incompetence, or temporary incapacity or the pregnancy 
resulted from rape or incest. 
f. Each individual providing consent here is fully informed regarding the 
reasonably foreseeable impact of the research on the fetus; 
g. Pregnant children must assent and obtain permission in accord with 
subpart D; 
h. No inducements, monetary or otherwise, will be offered to terminate a 
pregnancy; 
i. Individuals engaged in the research will have no part in any decisions as to 
timing, method, or procedures used to terminate a pregnancy. 
j. Individuals engaged in research will have no part in determining viability.  
 
The aforementioned regulations provide IRBs ten requirements for selecting 
pregnant women in clinical research. First, the regulations require a prerequisite to 
                                                        
56 Id. 
57 Comparison of FDA and HHS Human Subject Protection Regulations, FDA.GOV, 
http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/educationalmaterials/ucm11291
0.htm (last visited May 6, 2014). 
58 45 C.F.R. § 46.204.  
 11 
research to conduct studies on non-pregnant women first. This condition is that 
preclinical studies must be conducted to provide data for an assessment of potential risks 
to pregnant women and fetuses. A concern is that a precondition of preclinical studies on 
non-pregnant women is that pregnant women are neglected or excluded from research. 
This requirement is to ensure that safety trials are ethical and do not expose the fetus to 
potential adverse harms. The Department agreed and noted that preclinical and clinical 
studies are required only when scientifically appropriate.59 
Second, terminology in the regulations requires IRBs to determine the meaning of 
minimal risk and direct benefit. The regulations require that if there is no prospect of 
benefit from the trial, the risk to the fetus must not be greater than minimal. This means 
that the risk to the fetus is the least possible risk for achieving research objectives and any 
greater risk must be a direct benefit to the fetus or woman. However, there is a great 
problem amongst IRBs in determining the meaning of this phrase because “no more than 
minimal risk is extremely vague and interpreted by different IRBs in radically different 
ways.”60 Additionally, IRBs are also left to determine the meaning of direct benefit, and 
whether there is a high probability of direct benefit, or if the probability is even relevant. 
Subpart B grants IRBs the opportunity and the authority to ensure the adequacy of 
informed consent and protections by imposing additional requirements and monitoring 
the research or consent process.61 The Department recognizes and encourages paternal 
involvement in decisions affecting the pregnant woman and fetus prior to delivery, 
                                                        
59 Protection of Human Research Subjects, 66 Fed. Reg. 3878-01, 3880 (Jan. 17, 2001) (to be codified at 45 
C.F.R. pt. 46). 
60 Regulatory Fixes And Clarification Needed For Involving Pregnant Women In Clinical Trials, 18 NO. 5 
GUIDE TO GOOD CLINICAL PRACTICE NEWSL. 10 (Feb. 2011). 
61 Protection of Human Research Subjects, 66 Fed. Reg. 3878-01 at 3880. 
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although there is a concern that the paternal consent is a barrier. 62  However, the 
regulations note that consent is not needed if the father is unavailable. Ultimately, the 
Department concluded that the decision-making authority for research participation of the 
pregnant woman or fetus prior to delivery should rest with the pregnant woman.63 
B. FDA and the Enrollment of Pregnant Women in Clinical Trials  
The DHHS Protection of Human Subjects Regulations categorizes pregnant 
women as a vulnerable population and contains rules and guidance for research with 
pregnant women. While DHHS has special subparts relating to research for vulnerable 
populations, such as prisoners, and pregnant women, the FDA does not have comparable 
provisions for these populations.64  
1.  FDA Tools to Ensure Demographic Data Analysis 
 
In 1998, the FDA amended its regulations to require effectiveness and safety data 
for demographic subgroups, specifically gender, age and racial subgroups.65 Therefore, 
the FDA is permitted to place a clinical hold on one or more studies under an IND if a 
sponsor proposes to exclude gender from participation in an investigation only because of 
risk or potential risk from the use of an investigational drug.66 Furthermore, in 2007, the 
FDA required that prescription drug products must contain specific information about use 
in specific populations in the contents of drug labeling. 67  In a 2013 FDA report, a 
working group found that the FDA’s internal policies, procedures and regulations 
facilitate the assessment of demographic subgroup information included in marketing 
                                                        
62 Id. 
63 Id. 
64 Comparison of FDA and HHS Human Subject Protection Regulations, FDA.GOV, 
http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/educationalmaterials/ucm11291
0.htm (last visited May 6, 2014). 
65 See 21 CFR §§ 312, 314. 
66 21 C.F.R. § 312.42. 
67 21 C.F.R. § 201.56(7). 
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applications.68 The FDA can communicate demographic information to the public after 
marketing approval through a variety of mechanisms, including product labeling, publicly 
posted clinical reviews, consumer updates, safety alerts, and label changes.69 
While the FDA shifted their approach from excluding women in research to 
allowing women, the agency does not actively require or regulate research in pregnant 
women. The agency requires IND applications to include reports by sex; however the 
breakdown in this data is only male and female. The FDA fails to make an affirmative 
requirement to collect data on any pregnant woman involved in a clinical trial. 
Additionally, the FDA issued draft guidance for a basic framework for designing 
and conducting clinical studies in pregnant women, 2004 Guidance for Industry 
Pharmacokinetics in Pregnancy - Study Design, Data Analysis, and Impact on Dosing 
and Labeling. The draft guidance provides recommendations to sponsors on how to 
assess the influence of pregnancy on the pharmacokinetics and the pharmacodynamics of 
drugs, as well as recommendations for investigators and researchers about issues to 
consider when designing and conducting PK studies in pregnant women.70  The guidance 
adopts 45 C.F.R. § 46.204, stating that  
Pregnant women may be involved in PK studies if the following 
conditions are met: preclinical studies, including studies on pregnant 
animals, and clinical studies, including studies on nonpregnant women, 
have been conducted and provide data for assessing potential risk to 
pregnant women and fetuses; and the risk to the fetus is not greater than 
minimal and the purpose of the research is the development of important 
                                                        
68 U.S. DEPT. OF HEALTH & HUMAN SERVS., FOOD & DRUG ADMIN., Collection, Analysis, and Availability 
of Demographic Subgroup Data for FDA-Approved Medical Products (2013) available at 
http://www.fda.gov/downloads/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/sig
nificantamendmentstothefdcact/fdasia/ucm365544.pdf. 
69 Id. 
70 CENTER FOR DRUG EVALUATION & RES., U.S. FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY: 
PHARMACOKINETICS IN PREGNANCY –STUDY DESIGN, DATA ANALYSIS, AND IMPACT ON DOSING AND 
LABELING (Oct. 29, 2004) [hereinafter 2004 FDA DRAFT GUIDANCE]. 
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biomedical knowledge which cannot be obtained by any other means.71  
 
The FDA acknowledges that the definition of minimal risk is broad and states that “fetal 
risk is considered minimal when the estimated risk to the fetus is no more than that from 
established procedures routinely used in an uncomplicated pregnancy or in a pregnancy 
with complications comparable to those being studied.”72 The guidance anticipates that 
most of the studies in pregnant women will occur postmarketing from pregnant women 
who have already been prescribed the drug.73 
This draft guidance does not encourage or incentivize industry or researchers to 
actively enroll pregnant women in studies. Clear agency guidance with affirmative 
actions items, such as the mandatory collection of postmarketing data or an active 
approach to recruitment, would enable the FDA to increase enrollment.  
2.  FDA Tools to Collect Data on Medications Taken During Pregnancy  
 
The FDA published pregnancy exposure registry guidelines in 2002 and 2005, to 
encourage the collection of and to facilitate the analysis and interpretation of data 
regarding medication exposure during pregnancy.74 These pregnancy exposure registries 
are a prospective observational study that examines fetal risk from medication exposure 
during pregnancy in which the enrollment criteria includes pregnant women already 
taking the medication where fetal outcomes have not yet been ascertained.75 
When drug safety data is collected after a drug is licensed, problems may arise, 
such as the “lack of information about confounding factors, maternal adherence to 
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prescribed medication, use of over-the-counter medicines…and difficulty in evaluating 
longer term effects.”76 The FDA has not made pregnancy exposure registries mandatory 
for manufacturers to track data, but left this responsibility to the pregnant women taking 
the drug.77 The agency explicitly states “since drug companies can’t test medicine on 
pregnant women, they may have little or no information about how these medicines could 
affect a woman or her fetus. Pregnancy registries are the best way to learn and to help 
women decide about taking medicines.” 78  The FDA had the opportunity to require 
industry to take a proactive approach to this research but failed to make this a 
requirement. 
C. Non-binding Guidance Includes Pregnant Women in Clinical Research 
 International and professional committees provide clearer guidance to include 
pregnant women in research. There is an opportunity to shift the paradigm from 
excluding pregnant women in clinical research to a presumption that pregnant women are 
eligible for relevant research.  
 The Council for International Organizations of Medical Science guidelines, 
International Ethical Guidelines for Biomedical Research Involving Human Subjects, 
relate mainly to ethical justification and scientific validity of research. 79 However, there 
is an explicit provision for pregnant women as research participants, which states 
                                                        
76 Thomas & Yates, supra note 10. 
77 See How To Sign Up for a Pregnancy Exposure Registry, FDA.GOV, 
http://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm252397.htm (last visited 
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makes the medicine is usually in charge of the pregnancy registry. There is a list of medications available 
with a telephone number and link to connect the pregnant woman to the company in charge of the registry.  
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79 Council for International Organizations of Medical Sciences, International Ethical Guidelines for 
Biomedical Research Involving Human Subjects, Geneva, 2002, at 74, available at (http:// 
www.cioms.ch/publications/layout_guide2002.pdf)  (last visited May 6, 2014) (CIOMS is an international, 
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Pregnant women should be presumed to be eligible for participation in 
biomedical research. Investigators and ethical review committees should 
ensure that prospective subjects who are pregnant are adequately informed 
about the risks and benefits to themselves, their pregnancies, the fetus and 
their subsequent offspring, and to their fertility. Research in this 
population should be performed only if it is relevant to the particular 
health needs of a pregnant woman or her fetus, or to the health needs of 
pregnant women in general, and, when appropriate, if it is supported by 
reliable evidence from animal experiments, particularly as to risks of 
teratogenicity and mutagenicity.80 
 
CIOMS justification of research involving pregnant women recognizes that it is 
complicated by the fact that it may present risks and potential benefits to two beings, the 
woman and the fetus, as well as to the person the fetus is destined to become.81 The 
commentary states that special safeguards should be established to prevent undue 
inducement to pregnant women to participate in research in which interventions hold out 
the prospect of direct benefit to the fetus. 82  Finally, the commentary states that 
investigators should include in protocols on research on pregnant women a plan for 
monitoring the outcome of the pregnancy with regard to both the health of the woman 
and the short-term and long-term health of the child.83 This guidance is clear in stating 
that pregnant women should be presumed eligible for participation in clinical research. A 
presumption of eligibility will deter the fear of the overbroad presumption of ineligibility.  
 A 2005 guideline from the European Medicines Agency, Guideline on the 
Exposure to Medicinal Products During Pregnancy, proposed active surveillance for the 
collection of post-authorization data in pregnancy.84 
 The American Congress of Obstetricians and Gynecologists issued a 2007 
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84 See Ruth Macklin, Enrolling Pregnant Women In Biomedical Research, 375 LANCET 632, 635 (2010) 
(noting that the guideline is applicable to newly marketed drugs and recommends a similar plan for older 
drugs lacking data). 
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Committee Opinion designed to provide reasonable guidelines for research involving 
women.85 This opinion affirmatively states: 
All women should be presumed to be eligible for participation in clinical 
studies. The potential for pregnancy should not automatically exclude a 
woman from participating in a clinical study, although the use of 
contraception may be required for participation. Inclusion of women in 
clinical studies is necessary for valid inferences about health and disease 
in women. The generalization to women of results from trials conducted in 
men may yield erroneous conclusions that fail to account for the biologic 
differences between men and women.86 
 
ACOG’s Committee on Ethics affirms both the need for women to serve as participants 
in research and the obligation for researchers, IRBs, and others reviewing clinical 
research to evaluate the potential effect of proposed research on women of childbearing 
potential, pregnant women, and the developing fetus.87 
 ACOG explicitly states that pregnancy should not automatically exclude a woman 
from participating in a study. However, as Part IV of this paper examines, most studies 
categorize pregnant women as part of the exclusionary criteria. ACOG’s non-binding 
guidance recognizes the need to include women in studies but falls short of the 
presumption of eligibility for pregnant women to participate.   
IV. TODAY’S ENVIRONMENT: BURDENS TO OVERCOME TO INCREASE ENROLLMENT OF 
PREGNANT WOMEN IN CLINICAL RESEARCH 
 
The current clinical trial landscape does not demonstrate an inclusionary approach 
of pregnant women in clinical research. Despite the need to include pregnant women in 
drug trials, there is not a big push to enroll this population.88 For example, only one drug, 
Makena, has been approved by the FDA for pregnancy indications in the past five 
                                                        
85 Research Involving Women, ACOG Committee Opinion No. 377. AM. C. OBSTETRICIANS & 
GYNECOLOGISTS (2007).  
86 Id. 
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88 S Endicott & DM Haas, The current state of therapeutic drug trials in pregnancy, 92 CLINICAL 
PHARMACOLOGY & THERAPEUTICS 149, 150 (2012). 
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years.89 
A. Clinical Trials Do Not Actively Recruit Pregnant Women 
Using the NIH database for clinical trials, an analysis of Phase I, II and III studies 
for both industry and NIH or government funded including “pregnant” supports the gross 
underrepresentation of pregnant women in research. 90  Out of the 166,199 studies 
registered with ClinicalTrials.gov, there are 1,686 studies that include the term 
“pregnant.”91 For trials sponsored by the NIH or other government funding, there are 
currently 71 studies in Phase I that include the term “pregnant,” 65 studies in Phase II, 
and 97 studies in Phase III.92 For trials sponsored by industry, there are currently 9 
studies in Phase I that include the term “pregnant,” 14 studies in Phase II, and 29 studies 
in Phase III. 93  However, these numbers overstate studies including pregnant women 
because the search returned studies in which “pregnant” was listed as an exclusion 
criteria. The few drug and biologic studies actively recruiting pregnant women were for 
HIV, influenza, malaria or a pregnancy related conditions.  
 According to this analysis using the NIH database, only two trials from NIH 
sponsors actively recruited pregnant women for a condition other than HIV, influenza, 
malaria or pregnancy related condition. The NIH or government funded studies yielded 
only two trials of interest. A Phase I vaccine trial was conducted in 48 pregnant women 
and 32 non-pregnant women to look at the safety and immunogenicity of a combination 
                                                        
89 Id at 149. 
90 Search for Studies, CLINICALTRIALS.GOV, http://clinicaltrials.gov (follow “advanced search” hyperlink; 
then search term “pregnant,” select study type “interventional studies,” select Phase “1” “2” and “3;” then 
follow “search” hyperlink) [hereinafter CLINICALTRIALS.GOV DATABASE SEARCH].  
91 Id.  
92 See CLINICALTRIALS.GOV DATABASE SEARCH, supra note 90 (follow search but select funder type 
“NIH,” “other US agency” and “all others;” then follow “search” hyperlink). 
93 See CLINICALTRIALS.GOV DATABASE SEARCH, supra note 90 (follow search but select funder type 
“industry;” then follow “search” hyperlink). 
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vaccine. 94  A Phase III trial for diabetic pregnant women actively recruited pregnant 
women with insulin-resistant diabetes mellitus, yet excluded pregnant women with type-I 
diabetes.95 Noticeably absent were studies involving depression, asthma or hypertension. 
 The second interesting finding from the NIH database is that, out of the 52 studies 
containing the term “pregnant” in industry sponsored studies, zero studies actively 
recruited pregnant women for a condition other than HIV, influenza, malaria, or 
pregnancy related condition. 96  Pfizer and Cedars-Sinai Medical Center terminated a 
study, which recruited both men and women for the treatment of anxiety disorder.97 
While this study excluded pregnant women, the study required “partners of male 
participants who become pregnant during the course of the study to participate in order to 
collect safety information and understand the effects, if any, that the investigational drug 
may have on her pregnancy or the fetus.”98 Here, industry is excluding pregnant women 
from studies and failed to actively recruit pregnant women for chronic condition research. 
 A 2012 report found that in the past two years, 264 drug trials have been 
registered and or performed specifically in pregnant women.99 This report analyzed the 
ClinicalTrials.gov database with the keyword “pregnancy” and searched the abstracts 
from annual meetings from five organizations.100 However, the report found that it was 
impossible to determine how many of the trials were being performed on investigational 
drugs or where the funding came from because of inconsistent data between the website 
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and the organizations.101 But the report was consistent in finding that the most common 
treatment objectives of studies in pregnancy were antibiotic and anti-infective agents, 
including hepatitis, HIV and malaria, as well as preterm birth prevention, vitamin and 
nutrition supplements, diabetes and gestational diabetes, and labor induction.102 
Furthermore, a 2013 study concluded that out of 558 Phase IV studies, only five, 
or 1%, were designed specifically for pregnant women.103 This study also found that 95% 
of qualified studies explicitly excluded pregnant women, suggesting the exclusion to be 
common practice.104 These results demonstrate that industry is not conducting research 
on pregnant women in Phase IV studies. This information highlights the importance of 
changing the approach to clinical research in pregnant women. 
B. Drug Case Studies Associated with Birth Defects and Industry’s Response  
Physicians may fail to prescribe drugs during pregnancy because of the lack of 
data for drug safety, efficacy and dosage, or the fear of the unknown risk to the fetus. The 
failure to treat chronic illnesses such as depression, diabetes or asthma may cause 
significant harm to both the mother and the fetus. Pregnant women and physicians are 
faced with the challenging decision whether to use a medication without sufficient safety 
data or to stop medication. Researchers are faced with an ethical dilemma of when to 
enroll pregnant women in clinical research. Manufacturers lack an incentive to enroll 
pregnant women in research, even if safety in pregnant women may be a known issue. 
The use of medicines in pregnancy is increasing due to the increasing rates of 
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maternity in older women.105 There is a significant prescribing of drugs known to be 
associated with fetal risks, with 1-4% of women being prescribed medicines considered 
contraindicated.106 
This section discusses birth defects associated with drugs when taken during 
pregnancy and assesses whether the FDA and manufacturer responded appropriately.  
1.  Paxil Case Study: Is it Safer to take an Antidepressant or Discontinue 
Medication During Pregnancy?  
 
 In the case of depression, a pregnant mother is faced with the hard decision 
whether to stop using an antidepressant, or to continue using the antidepressant despite 
manufacturer warnings about possible fetal harm. Clear guidance for which treatment 
option is best for a pregnant mother suffering from a mental disorder that requires 
medication is nonexistent.  
 Antidepressants are widely prescribed for major depression and other psychiatric 
disorders and are considered the primary treatment for moderate to severe depression, 
although their effectiveness and safety during pregnancy have been studied 
infrequently.107 In pregnant women with depression, antidepressants have been shown to 
reduce symptoms, however discontinuation has been “associated with increased risk of 
antenatal depressive relapses.108 Furthermore, untreated gestational depression has been 
associated with “pre-eclampsia, preterm delivery, low birth weight, sudden infant death, 
developmental delay in offspring, post-partum depression and maternal suicide.”109 For 
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many years, selective serotonin reuptake inhibitors (SSRIs), “the most commonly 
prescribed antidepressants, were regarded as safe for use in pregnancy.”110 
 In 2004, the FDA issued public health advisories about the risk of perinatal 
complications with SSRIs and other antidepressants.111 These warnings were “prompted 
by increasing reports of adverse neonatal outcomes associated with maternal 
antidepressant use including potential risk for cardiovascular malformations.” 112 
However, the regulatory warnings did not advise against the use of antidepressants during 
pregnancy nor recommend antidepressant discontinuation.113 
 The FDA first approved Paxil, an SSRI to treat depression, in 1992.114 However, 
Paxil has been associated with a number of birth defects. In 2005 the manufacturer of 
Paxil told physicians that preliminary study results suggested an increased risk of 
congenital malformations associated with the use of Paxil during early pregnancy as 
compared with other antidepressants.115 The prescribing information for Paxil CR states 
that there are no adequate and well-controlled studies in pregnant women, and it should 
be used during pregnancy only if the potential benefit justifies the potential risk to the 
fetus.116 However, lawsuits charge that the manufacturer deliberately withheld what it 
knew about Paxil’s dangers to developing fetuses. 117  The manufacturers motion to 
dismiss various products liability claims was granted with respect to all claims, except the 
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failure-to-warn. 118  Specifically, after using Paxil while pregnant, plaintiff's infant 
daughter died sixteen days after birth from a congenital heart defect.119 After the infant's 
death, the manufacturer revised the warning label to indicate that there were no adequate 
studies of the drug in pregnant women and that one study indicated an increased risk of 
congenital cardiovascular malformations from use of paroxetine.120 
The failure to gather consistent data about safety of antidepressant use during 
pregnancy is a contributing factor to the well-known SSRI birth defects and is an 
example of the need for evidence-based data. With this data, consistency in safety for 
depression and pregnancy will be uniform.  
2.  Accutane Case Study: The FDA’s Response to Accutane Birth Defects 
 
Accutane (isotretinoin) is a highly effective treatment for severe recalcitrant 
nodular acne, but is known to cause serious birth defects when pregnant women use the 
drug.121 The manufacturers of Accutane and the FDA implemented a risk management 
program to educate women about the risk of becoming pregnant while taking this drug.122 
The iPLEDGE program is to prevent the use of Accutane during pregnancy and in order 
to obtain the drug, patients must register with iPLEDGE, and comply with a number of 
requirements that include completing an informed consent form, obtaining counseling 
about the risks and requirements for safe use of the drug, and, for women of childbearing 
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age, complying with necessary pregnancy testing.123 This risk management program is an 
example of a controlled data collection environment that will decrease birth defects. 
3.  Depakote ER Case Study: Abbott’s Unwillingness to Conduct Research in 
Pregnant Women  
 
 The FDA approved Depakote for marketing in 1983. 124  In 1996, Depakote 
(divalproex sodium), manufactured by Abbott Laboratories, was approved for the 
treatment of epilepsy and migraine headaches.125 In 2000, Depakote ER was approved for 
the prevention of migraine headaches in adults.126 The FDA warned Depakote ER had 
been associated with birth defects, specifically, spina bifida.127  
 In May 2013, the FDA released a Drug Safety Communication for Depakote ER, 
which stated a recent study showed children exposed to this class of drugs while their 
mothers were pregnant had decreased IQs.128 This warning also stated the FDA will 
advise manufacturers to change the pregnancy category129 for migraine use from “D” to 
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“X.” 130  According the to the prescribing information, Depakote ER is currently 
pregnancy category D for epilepsy and for manic episodes associated with bipolar 
disorder, and category X for prevention of migraine headaches. 131  The different 
pregnancy categories for the same product will likely lead to confusion amongst 
prescribers and women. 
 The FDA’s communication of contraindication, category X, for prevention of 
migraines in pregnant women does not provide clear guidance because it only warns that 
pregnant women taking this medication should not stop since stopping suddenly may 
cause life-threatening problems to the woman or baby.132 The FDA stated that it is not 
known if there is a specific time period for harm or when the exposure may be considered 
to have less risk for decreased IQ in children.133 This communication does not discuss the 
risks associated with Depakote ER for the original epilepsy indication. 
 The Depakote ER fetal risk knowledge gap from the approval to the subsequent 
black box warnings is alarming for three reasons. First, the method by which the data for 
fetal risk were obtained compared to the time on the market is a concern. Pregnancy 
registry data134 in combination with drug safety warnings suggest Abbott did not engage 
in any proactive studies to determine the safety of Depakote ER in pregnant women.135 
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 The second observation is the failure to require a mandatory exposure registry.136 
The prescribing information states that physicians “should encourage patients to enroll in 
the registry in order to collect information on the effects of in utero exposure to 
Depakote.”137 Abbott is not required to participate in the registry nor conduct further 
surveillance on pregnant patients taking Depakote ER. 
 The third observation is Abbott’s affirmative exclusion of pregnant women from 
clinical trials. According to the NIH database, Abbott sponsored a Phase III open label 
study in 2005 to determine the safety of Depakote ER in adolescents.138 In order to be 
eligible for the study, the participant had to be male, or a non-pregnant, non-lactating 
female. 139  The NIH database yielded zero studies including pregnant women and 
divalproex sodium. 
4.  Lessons Learned: If Industry, the Government and Manufacturers Aligned on 
Requiring Research in Pregnant Women, Could Birth Defects Decrease? 
 
Paxil, Accutane, and Depakote ER all caused serious birth defects in some women 
who took these prescriptions during pregnancy. Ethical concerns regarding the safety of 
medication on fetuses have been a driving force in the exclusion of pregnant women from 
clinical studies. However, the risk that should be considered is whether to expose a 
consenting pregnant woman to medication in a closely monitored research setting, instead 
of exclusion because of an unknown fear. If data were collected earlier, documentation of 
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known birth defects would decrease medication exposure and increase education. 
For example, when data became available about birth defects associated with 
Paxil, there was an opportunity to proactively obtain birth defect data. The FDA had the 
ability to require postmarketing surveillance as a condition of approval for Paxil in 
pregnant women.140 Furthermore, GSK did not provide the public with this information.  
Contrast Paxil to Accutane, where the FDA took a proactive role in ensuring that 
women do not become pregnant while taking the drug because of known serious birth 
defects. Additionally, if the manufacturer was required to collect pregnancy exposure 
data on Accutane before the staggering number of reported birth defects, there is a higher 
probability for a lower number of birth defects due to a proactive role. 
Lastly, in the case of Abbott, they failed to take a proactive approach to better 
understand known risks of exposure during pregnancy. Depakote was already associated 
with birth defects, but neither additional studies nor postmarketing surveillance on 
exposure were conducted.  
V. IMPROVE CLINICAL RESEARCH PROTOCOLS TO INCREASE ENROLLMENT OF PREGNANT 
WOMEN IN STUDIES 
 
 The harms of inadequate clinical research fall enormously on pregnant women, 
their fetuses, and children exposed to medication in utero. It is clear that research does 
not actively recruit pregnant women for chronic conditions such as diabetes, depression 
or hypertension. The result of the failure to study medication in pregnant women 
negatively impacts society, industry, and the ability to enroll pregnant women in studies.  
First, this recommendation addresses the ability to increase enrollment of 
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pregnant women in clinical trials by examining different approaches agencies may adopt. 
The four approaches suggest the least inclusive to most inclusive participation of 
pregnant women in research: (1) agency collaboration, (2) notice and comment period for 
proposed rulemaking, (3) incentive based program, and (4) mandatory requirements.  
A.  OWH & ORWH Collaboration to Develop Awareness, Education & Guidance 
 
 With the education of healthcare professionals, researchers and pharmaceutical 
manufacturers, there is an ability to increase the enrollment of pregnant women in clinical 
trials. The FDA’s OWH and the NIH’s Office of Research on Women’s Health (ORWH) 
must work collaboratively to issue updated guidance to communicate the importance of 
increasing the enrollment of pregnant women in clinical research.  
 First, the OWH141 and ORWH142 must update their mission and messaging to 
include pregnant women, not only women to eliminate the exclusionary approach of 
pregnant women in clinical studies. Noticeably absent from both organizations is 
pregnant women advocacy for both health and research.  
 Second, the OWH and ORWH must educate stakeholders and increase their 
awareness about the importance of pregnant women in clinical research. Awareness can 
be achieved by the publication of research, education, and guidelines. A collaboration of 
stakeholders to gather data must include guidance and decision makers, regulators, 
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payers, providers, researchers, IRBs, ethics committees, patients, and the public.143 
 Third, the OWH and ORWH must publish updated policies to increase awareness 
among the general public and key stakeholders. The FDA is holding a public meeting in 
May 2014 on study methodologies to evaluate the safety of drugs during pregnancy.144  
The FDA must also update their 2012 policy, Successful Strategies for Engaging 
Women and Minorities in Clinical Trials, because this policy does not address engaging 
pregnant women, but only offers strategies for diversity in trials by the recruitment of 
female physicians, trust, education through awareness, and community involvement.145  
B.  Notice and Comment Period for Rulemaking to the Common Rule  
 
 A notice of proposed rulemaking should be communicated about changes to the 
Common Rule. This notice will allow for public comment and require an answer and 
explanation from the OHRP. The proposed changes should remove pregnant women from 
the vulnerable population category and the paternal consent requirement in order to 
remove barriers to enrollment. The proposed changes should also adopt the FDA’s 
guidance definition of minimal risk to the fetus in order to further clarify the term 
minimal risk, obtain public comment, and allow for OHRP to respond. 
 First, the regulations must remove pregnant women from the vulnerable 
population category. The regulations define criteria for IRB approval of research as 
“when some or all of the subjects are likely to be vulnerable to coercion or undue 
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144 Meeting Notice, 79 Fed. Reg. 9469-02 (Feb. 19, 2014) (the purpose of this meeting is to obtain 
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145 Women in Clinical Trials, FDA.GOV, 
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influence…additional safeguards have been included in the study to protect the rights and 
welfare of these subjects.” 146  It is not appropriate to categorize pregnant women as 
vulnerable to coercion or undue influence. Coercion is defined as compulsion by physical 
force or threat of physical force, and undue influence is defined as the improper use of 
power in a way that deprives a person of free will and substitutes another's objective.147 
To group all pregnant women as a vulnerable population that is susceptible to physical 
force or subject to a deprivation of free will is inexcusable. The difference between 
pregnant women and the other vulnerable populations falls under decision-making 
ability. One cannot reasonably believe that pregnant women, as a whole, lack the ability 
to make their own autonomous decisions because they are vulnerable in society. 
 Second, the regulations should remove the paternal consent requirement. The 
Department recognizes and encourages paternal involvement in this decision making 
process, nevertheless, in some cases the father’s consent is a barrier to participation in 
research.148 General comments to the final rule for subpart B state “the recommendations 
of the National Task Force on AIDS Drug Development, the Presidential Advisory 
Council on HIV/AIDS, and the IOM Committee were unanimous that the consent of the 
father should not be a condition of the participation of a pregnant woman in research.”149 
The final rule also stated that some commenters described specific trials in which 
pregnant women were unable to participate in potentially beneficial research because 
they could not get paternal consent.150 The informed consent process deems the woman 
as sufficient to make her autonomous decision to engage in research and the paternal 
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consent should be removed due to it being a barrier. 
 Lastly, the Department should further define minimal risk. In FDA guidance, they 
acknowledge the definition of minimal risk is broad and state “fetal risk is considered 
minimal when the estimated risk to the fetus is no more than that from established 
procedures routinely used in an uncomplicated pregnancy or in a pregnancy with 
complications comparable to those being studied.”151 Therefore, regulations should adopt 
the FDA’s proposed definition of minimal risk in order to encourage researchers and 
IRBs to be more inclusive in enrolling pregnant women.152 
C.  Create Incentive Based Program to Increase Enrollment of Pregnant Women 
 
 Congress should expand the six-month pediatric patent exclusivity regulation to 
pregnant women. This would incentivize manufacturers to conduct studies in pregnant 
women, similar to the studies conducted in the pediatric population. 
Congress awards six months of patent exclusivity in return for conducting 
pediatric studies as a marketing incentive to manufacturers.153 The FDA requires that the 
manufacturer conduct the trials in order to receive the patent exclusivity for marketing.154 
The exclusivity is granted for conducting a valid study even if the information collected 
by the manufacturer does not demonstrate an effect or difference.155 
 The FDA may develop, prioritize, and publish a list of approved drugs for which 
additional pediatric information may produce health benefits in the pediatric 
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population.156 To determine the drugs on the list, the FDA used several criteria, consulted 
with experts, and made the draft list available for public comment.157 The criteria158 and 
therapeutic category159 were central to determine patent exclusivity.  
 There is a similar opportunity to increase the enrollment of pregnant women in 
research by creating a patent exclusivity incentive for manufacturers to conduct studies in 
pregnant women. Researchers are reluctant to conduct studies in pregnant women 
because of ethical concerns for adverse effects of medication exposure to the developing 
fetus.160 If the FDA expands 21 U.S.C. § 355a to research in pregnant women, the agency 
can educate researchers for when it is ethically appropriate to conduct research.161 
Pharmaceutical manufacturers have taken advantage of patent exclusivity for new 
pediatric drugs. As of February 2014, the FDA granted pediatric exclusivity for 216 
pediatric studies.162 An analysis of the 199 drugs that were granted exclusivity shows the 
predominance of top pharmaceutical companies receiving exclusivity periods for 
drugs.163  
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These data suggest that top manufacturers were able to meet requirements for 
research in pediatric populations when there was a potential for health benefit. Similar to 
pediatric research, manufacturers may choose when to conduct trials in pregnant women.  
D.  Mandatory Requirements to Increase Enrollment of Pregnant Women in 
Clinical Research 
 
 Congress, the FDA and the NIH have the ability to amend laws and regulations to 
increase the enrollment of pregnant women through the creation of new IND and NDA 
laws, defining subpopulation of women, and expanding pregnancy registries. 
 First, IND and NDA’s must require an assessment in pregnant women prior to 
approval of the drug or biologic. Under the current law, the FDA has the authority to 
require a pediatric assessment, which contains data adequate to assess safety and 
efficacy. 164  This pediatric population mandate has contributed data on drug labels 
“concerning the safe and effective use of more than 400 drugs in neonates, infants, 
children, and adolescents.”165 
 An adoption of a similar law for an assessment in pregnant women prior to 
approval, where scientifically appropriate, will increase evidence-based data. This law 
will adopt testing protocols similar to the Pediatric Research Equity Act, including 
allowing a waiver when a pregnant women assessment is not necessary. The pediatric 
population is also categorized as a vulnerable population, yet this law has proved 
successful in the ability to regulate and conduct clinical studies in pediatrics. Therefore, a 
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similar law must be enacted to increase pregnant women in clinical research. 
 Second, the FDA should expand NDA and IND demographic reporting for 
subgroups to include pregnant women and non-pregnant women. Federal regulations 
require NDA’s to present effectiveness and safety data for important demographic 
subgroups, specifically gender.166 One public comment to the FDA requested a definition 
for subpopulations of women because “safety, pharmacokinetic, and efficacy data for 
pregnant women should be presented separately from data for women who are not 
pregnant.”167 However, the FDA declined to define subpopulations of women because “it 
is not necessary…and usually pregnant women would only participate in clinical trials 
intended specifically to study drug effects during pregnancy. The data generated from 
such trials would, therefore, reflect use in this subpopulation of women.”168 
 The FDA should not decline to define subpopulations of women. The response 
that data generated from trials that were specifically intended to study drug effects during 
pregnancy is unsatisfactory based on today’s clinical trial landscape. Manufacturers and 
the NIH are not conducting any trials in pregnant women to determine safety and efficacy 
of drugs for chronic conditions such as diabetes and hypertension. Trials do not reflect a 
breakdown of subpopulations for pregnant and non-pregnant. A requirement for a trial to 
provide a women subpopulation is an appropriate response. 
 Lastly, Congress should expand the law to require pregnancy exposure registries 
as a condition for approval for drugs in Category C, D, or X. As part of the expansion of 
pregnancy exposure registries, the FDA should also issue guidance for manufacturers to 
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become involved in the process by creating a portal for patients to enroll in a registry for 
a product that is C, D or X. The FDA has the authority to require drug makers to study 
the effects of newly approved medicines on pregnant and nursing women and newborn 
infants, therefore the FDA must decide if the manufacturer should be required to set up a 
pregnancy registry as a condition of approval.169  
 The FDA does not maintain the pregnancy registries, although there is a partial 
list available on the OWH website. The law must require registries as a condition of 
approval for Category C, D and X drugs as well as postmarketing surveillance.170 The 
expansion of this law allows for the FDA to require the collection of data in pregnant 
women with the ultimate goal to decrease birth defects and promote awareness about the 
importance of obtaining evidence-based medicine in pregnancy.   
CONCLUSION 
 
Awareness, education, incentive programs, or mandatory requirements from 
DHHS will resolve the conflict of obtaining evidence-based data for prescriptions taken 
during pregnancy as well as increase enrollment of pregnant women in clinical trials. The 
harms of inadequate clinical research fall on pregnant women, fetuses, and children. Over 
the past twenty years, women may participate in clinical research, but as the current 
clinical trial landscape demonstrates, researchers and industry do not enroll or recruit 
pregnant women. Pregnant women must be afforded the same rights, advocacy, and data, 
and it is up to the industry and government to provide a different approach and ensure 
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improved methodologies to clinical research. 
